Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 12NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 278Lung Neoplasms 257Small Cell Lung Carcinoma 82Breast Neoplasms 59Mesothelioma, Malignant 49Adenocarcinoma of Lung 43Pancreatic Neoplasms 37Colonic Neoplasms 37Neoplasms 32Prostatic Neoplasms 30Ovarian Neoplasms 28Esophageal Neoplasms 26Neoplasm Metastasis 24Mesothelioma 24Melanoma 24Adenocarcinoma, Bronchiolo-Alveolar 24Stomach Neoplasms 22Colorectal Neoplasms 22Carcinoma, Renal Cell 22Rectal Neoplasms 20Urinary Bladder Neoplasms 18Uterine Cervical Neoplasms 17Squamous Cell Carcinoma of Head and Neck 17Carcinoma, Hepatocellular 17Brain Neoplasms 17Lymphoma, Non-Hodgkin 16Carcinoma, Ovarian Epithelial 16Thymoma 15Salivary Gland Neoplasms 15Lymphoma 15

Interventions

amatuximab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Carcinoma, Pancreatic Ductal × Thoracic × Clear all
NCT01413451 2019-12-17

Amatuximab for High Mesothelin Cancers

National Institutes of Health Clinical Center (CC)

Phase EARLY_PHASE1 Terminated
7 enrolled
GastrointestinalGynecologicOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Ovarian Neoplasms, Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡